Aarca Research

Research-driven innovations for the Continuum of Care.

[Aarca Research @AarcaResearch]

Varicose veins affect nearly 1 in 4 adults! It’s one of the most common vascular conditions worldwide. Yet, many people continue to ignore the signs. Unfortunately, varicose veins can be associated with chronic venous disease.

It's time to get screened @ https://t.co/e3z50dYh0n

[Aarca Research @AarcaResearch]

@AarcaResearch has been featured by the Government of India’s NITI Aayog as part of the NITI Frontier Tech Hub, recognising Aarca Research’s work in transforming circulation screening and preventing vascular complications.
https://t.co/uwqvsXlVig

#vascularhealth #savelimbs

[Aarca Research @AarcaResearch]

This recognition reinforces the direction we’ve chosen: deep research, rigorous clinical work, and products built for real-world impact. Link: https://t.co/qYmj4RwJLi

[Aarca Research @AarcaResearch]

Aarca Research has been awarded the Organisation of Pharmaceutical Producers of India "Excellence in Innovation Award for Healthcare Start-up of the Year 2025" for our product NerveVue.

[Matter of MedTech @matterofmedtech]

100 days, 100 startups!
@AarcaResearch
They are redefining metabolic health through cutting-edge, non-invasive technologies that enable early detection, continuous monitoring, & proactive management of health conditions.
Founded in 2019 by GayathriChoda @Gchoda

[Aarca Research @AarcaResearch]

Thank you!

#NerveVue

@Pharmadept @NITIAayog @AIMtoInnovate @NIPERAHM @pfizer @SocialAlphaIN @murata

[ETPharma @ETPharma]

Pfizer INDovation awards Rs 1.5 crore to 6 start-ups

#healthcaresolutions | #clinicalstudies | #medtechinnovations | #PfizerIndovationProgram |
Read more:
https://t.co/FAt5oOVMhR

[Raghunath Mashelkar @rameshmashelkar]

#Happy_Independence_Day to every citizen of our beloved nation.

In the upcoming national agenda, #HealthForAll through #AyushmanBharat #BanegaSwasthIndia have to be our topmost priorities.

Here is our own very humble effort through Anjani Mashelkar Foundation to create the magic of healthcare equality despite income inequality.

How? Through high-technology, ultra-affordable, disruptive healthcare solutions
https://t.co/MtjPcZWNnq

Here are only some of our stars…

◦iBreastExam, is a painless, ultra low cost, hand-held, radiation-free, ultra- portable breast cancer screening device that allows early screening of lumps in the breast, giving instant results! 2M+ scans have been done in 20+ countries
◦Oralscan is a hand-held, non-invasive, pain-free optical imaging multimodal device used for identifying pre-cancerous lesions of the oral cavity at as low as INR 200 per scan- saving time, cost and pain of multiple biopsies.
◦Dozee is a contact-free, AI-backed, remote monitoring (RMS) and early warning system (EWS) that provides timely alerts to healthcare staff minimizing the risk of deaths for patients undergoing critical care. 14000+ beds in 200+ hospitals in India are now ‘Dozee’ beds.
◦SanketLife is a credit card-sized, 12-lead, ultra-affordable, portable ECG which connects wirelessly and records ECG graphs on a smartphone. It has recorded 3 million+ ECGs so far in 12 countries.
◦Swaasa, is a ‘software as a medical device’ solution which offers early screening of respiratory problems by coughing into a smartphone!
◦IHRA (Intelligent Health Risk Assessment) is a software solution which offers early detection of metabolic disorders by taking 1 min video of the face long before the condition is clinically diagnosed, at as low as INR 50 per test!

And there are many more…👇👇

#digitalhealthmission #ncd #AyushmanBharat #cancerawareness

@PMOIndia, @IndiaDST, @DBTIndia, @CSIR_IND, @mygovindia, @MoHFW_INDIA, @BMCMumbai

[Aarca Research @AarcaResearch]

Granted patent for @AarcaResearch, by USPTO "US20220304578: Non-invasive, non-contact system and method for measuring Diabetes Mellitus condition using thermal imaging"

This is an important patent for the work we do in advancing healthcare technology

#Healthtech #Type2Diabetes

[nasscom startups @nasscomstartups]

This #WorldHealthDay, we acknowledge the role of technology in revolutionizing #healthcare, particularly in diabetes management. @AarcaResearch, is pioneering non-invasive diagnosis and maintenance procedures for diabetes and hypertension through innovative technology.

[Aarca Research @AarcaResearch]

Join us at @BioAsiaOfficial organised by Government of Telangana in collaboration with Lifesciences and Pharma Telangana.@TS_LifeSciences

[Aarca Research @AarcaResearch]

@rameshmashelkar @PuneIntCentre Thank you @rameshmashelkar sir for this great honour and your encouragement. We will strive hard to fulfil the responsibilities this prestigious prize bestows on us. #AnjaniMashelkarPrize

[Pune Int Centre @PuneIntCentre]

Congratulations, @AarcaResearch @Gchoda for winning the 13th Anjani Mashelkar Prize @Mashelkar_Fndn

Aarca Research provides first-of-its-kind technology to conduct health screenings by non-invasive methods.
🔗More https://t.co/7ebENFiiuB

@rameshmashelkar @sushilborde @girbane @abhay_vaidya

[Aarca Research @AarcaResearch]

Thank you @rameshmashelkar sir for this great honour and your encouragement. We will strive hard to fulfil the responsibilities this prestigious prize bestows on us.

#Healthtech #Innovation #AnjaniMashelkarPrize @Gchoda

[Raghunath Mashelkar @rameshmashelkar]

Here is the winner of much awaited 13th Anjani Mashelkar prize awarded in the inaugural function of @PuneIntCentre flagship National Conference on Social Innovation

Did you ever imagine, just by scanning your finger tips, you could uncover crucial insights about your metabolic health and predict the risk of conditions like diabetes, hypertension, high cholesterol?

The 13th Anjani Mashelkar Prize awardee Gayathri made this possible through her innovative solution – Intelligent Health Risk Assessment (IHRA) - a first-of-its-kind, ultra-affordable, early screening solution for detection of Type 2 Diabetes, Hypertension, and High Cholesterol using completely non-invasive technology- and that too for less than INR 10 per scan

Gayathri Choda, Founder and CEO of Aarca Research Pvt. Ltd., offers a disruptive, pain-free and cost-effective solution providing a real-time metabolic health panel including 18 parameters- just by inserting fingers into a socket of sensors!

Aarca Research has already touched the lives of many with ~15,000 screenings conducted across India and is aiming to reach ~6.5 million individuals over the next three years through ongoing partnerships.

[Longevity Industry Analytics @AgingAnalytics]

Explore the AI in Diabetes platform for comprehensive industry insights, featuring profiles, mindmaps, and databases of 16 companies, 95 investors, and 40 hubs in the field.

Discover more at https://t.co/C5uVeno8Ca
https://t.co/6JmYBlmIwF

#ai #artificialintelligence #startups

[Longevity Industry Analytics @AgingAnalytics]

Immerse yourself in our dynamic database showcasing the Top 100 AI Experts in Diabetes. This interactive platform features profiles of leading researchers, data scientists, endocrinologists, and technologists.

Learm more at https://t.co/YbgrNn0YoA

#ai #artificialintelligence

[Aarca Research @AarcaResearch]

Deutsche Welle (DW) review of state of Type 2 Diabetes and related solutions in India, and quotes about Aarca Research: https://t.co/KaIlikqysx

[JioGenNext @JioGenNext]

Listen to Gayatri Choda, Co-founder, Aarca Research who shares her startup journey on this International Women’s Day. Gayatri calls for encouraging women-led ideas and nurturing their execution capabilities.

#Womenfounder #IWD #Jiogennext #healthtech
https://t.co/HfdKDeIqXi

[Aarca Research @AarcaResearch]

News write-ups about @AarcaResearch during #BioAsia2023

Links:
T News: https://t.co/aP5wnc1g1D
Namasthe Telangana: https://t.co/Zd43qLHHJM and https://t.co/f16tOJVDlo
V6: https://t.co/is9mYaungi

[Aarca Research @AarcaResearch]

We are going to be at the startup Stage at @BioAsiaOfficial, scheduled for February 24-26, 2023.
Connect with at #BoothP1 during your visit.

[Aarca Research @AarcaResearch]

Excited to share our clinical trial results in the peer-reviewed international journal: International Journal of Scientific Research (DOI : 10.36106/IJSR), October 2022 edition. Impact factor score of the journal is 5.711 https://t.co/o27QC5A8Wt